Drugs / Human Butyrylcholinesterase
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00333528 | Dec 2007 → Apr 2008 | — | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 1 | NCT00333515 | Jan 2007 → Apr 2008 | — | Baxalta now part of Shire | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Butyrylcholinesterase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00333515 ↗ |
| Known as | HuBChE | “Human Butyrylcholinesterase (HuBChE) derived from human plasma” NCT00333515 ↗1“Human butyrylcholinesterase (HuBChE) derived from human plasma” NCT00333528 ↗ |
| Modality | Protein / enzyme biologic | “Plasma-Derived Human Butyrylcholinesterase (HuBChE)” NCT00333515 ↗ |
| Route | Intravenous | “Administration via IV infusion at a rate of 50 mg/min (2 mL/min)” NCT00333515 ↗ |